[Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].

作者
E Briët,Mauser-Bunschoten Ep
出处
期刊:PubMed [National Institutes of Health]
卷期号:141 (52): 2566-71 被引量:3
链接
标识
摘要

Haemophilia is an X-linked clotting disease occurring in 1400 men in the Netherlands. As the result of factor VIII or IX deficiency, haemophilia patients suffer from severe bleedings, spontaneous or caused by trauma. Bleedings mostly occur in major joints and muscles. Repeated bleedings can cause disability. Treatment of haemophilia consists of replacement therapy with factor VIII or IX. The first aim of treatment is to prevent bleedings (prophylaxis). The second aim is to limit joint damage in case of bleeding by timely and adequate substitution therapy. In addition, physical therapy and sports are used to keep patients in shape. Until the introduction of recombinant factor VIII in 1992 only plasma derived factor VIII and IX products were available. Substitution therapy has caused various side effects, such as allergic reactions. Since the introduction of ultra-pure concentrates, allergic reactions have grown rare. Viral infections like HIV and hepatitis C, which were transmitted through blood products, have not occurred in Dutch haemophilia patients since the introduction of adequate viral inactivation steps. In case of development of antibodies against factor VIII or IX, therapy with factor VIII or IX products is insufficient. Antibody formation is more often seen in haemophilia A (25%) than in haemophilia B (2%). In most cases antibodies disappear during so-called immune tolerance induction. This therapy consists of regular infusion with factor VIII or IX. Once an inhibitor has disappeared, patients can be treated normally once more. As haemophilia is a rare and complex disease patients should be treated in specialized centres, preferably by a comprehensive care team. This is even more justified because treatment of haemophilia is costly. Over the last 20 years haemophilia treatment has improved much. This has resulted in a decrease of the number and of the duration of hospitalization, and a decrease in days lost at school or work. This has led to great improvement of the social life of haemophilia patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小乔完成签到 ,获得积分10
4秒前
5秒前
lzl17o8发布了新的文献求助10
5秒前
铃溪完成签到,获得积分10
7秒前
xiaohululu发布了新的文献求助10
7秒前
7秒前
Hello的应助被闭家锁采纳,获得10
7秒前
7秒前
天天快乐的应助被科研通管家采纳,获得30
7秒前
8秒前
慕青的应助被科研通管家采纳,获得30
8秒前
科研通AI2S的应助被科研通管家采纳,获得20
8秒前
FashionBoy的应助被科研通管家采纳,获得10
8秒前
乐乐的应助被科研通管家采纳,获得10
8秒前
彭于晏的应助被科研通管家采纳,获得150
8秒前
星辰大海的应助被科研通管家采纳,获得10
8秒前
烟花的应助被科研通管家采纳,获得10
8秒前
8秒前
所所的应助被科研通管家采纳,获得10
9秒前
完美世界的应助被科研通管家采纳,获得10
9秒前
CipherSage的应助被科研通管家采纳,获得10
9秒前
9秒前
上官若男的应助被科研通管家采纳,获得10
9秒前
9秒前
9秒前
爆米花的应助被科研通管家采纳,获得10
9秒前
10秒前
科研通AI6.4的应助被二二春采纳,获得10
10秒前
majiaqi完成签到,获得积分10
12秒前
12秒前
12秒前
12秒前
唤年完成签到,获得积分10
15秒前
顺利毕业发布了新的文献求助10
15秒前
xiaohululu发布了新的文献求助10
16秒前
16秒前
妮娜发布了新的文献求助10
17秒前
22秒前
zyx发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)通过应助OA文献获取积分 10000
Composite Materials Handbook Volume 1 - Revision H 1000
Composite Materials Handbook Volume 3 - Revision H 1000
Rosenblum, Global Change Biology 800
Computational Chemical Reaction Engineering: Modeling, Simulation, and Design with MATLAB 600
Organizational Behavior 510
Management and the Arts 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 内科学 物理 有机化学 化学工程 生物化学 复合材料 光电子学 细胞生物学 心理学 量子力学 催化作用 物理化学 电极
热门帖子
关注 科研通微信公众号,转发送积分 7805524
求助须知:如何正确求助?哪些是违规求助? 9339206
关于积分的说明 20495093
捐赠科研通 7397861
什么是DOI,文献DOI怎么找? 3327889
关于科研通互助平台的介绍 2474667
邀请新用户注册赠送积分活动 2346007